tiprankstipranks
Eliem Therapeutics Expands Portfolio with Strategic Tenet Acquisition
Company Announcements

Eliem Therapeutics Expands Portfolio with Strategic Tenet Acquisition

Don't Miss our Black Friday Offers:

Eliem Therapeutics (ELYM) has issued an announcement.

The Company recently completed its acquisition of Tenet, with the deal finalizing on June 27, 2024. This strategic move involved the Company taking on several agreements, including an asset purchase agreement with Acelyrin, which grants them worldwide licenses to develop and commercialize TNT119, a non-oncology drug, along with associated obligations and milestones payments. Additionally, the Company issued over 5.5 million shares to Tenet’s equityholders as part of the acquisition’s terms. The agreements with CRH and ProBioGen were also part of the acquisition, providing the Company with exclusive and non-exclusive licenses respectively for the development of TNT119. These agreements come with their own sets of financial commitments, including milestone payments and royalties. Concurrently, the Company raised $120 million through a Private Placement and appointed new leadership, with Dr. Aoife Brennan as CEO and Dr. Stephen Thomas as a Board director and consultant.

For a thorough assessment of ELYM stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyEliem Therapeutics to change corporate name to Climb Bio
TipRanks Auto-Generated NewsdeskEliem Therapeutics: Executive Changes Amid Strategic Shift
TipRanks Auto-Generated NewsdeskEliem Therapeutics Names Brett Kaplan as New COO
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App